In this study, determination of terbinafine and itraconazole down to biological concentration level has been carried out. The determination is based on increasing the selectivity of the spectrofluorimetric technique by combining both derivative and synchronous spectrofluorometric approaches, which permits successful estimation of terbinafine at 257 nm and itraconazole at 319 nm in the presence of each other at Δλ of 60 nm. International Conference on Harmonization validation guidelines were followed to fully validate the method, and linearity was obtained for the two drugs over the range of 0.1–0.7 µg ml⁻¹ for terbinafine and 0.5–4.0 µg ml⁻¹ for itraconazole. Application of the method was successfully carried out in the commercial tablets with good agreement with the comparison spectrofluorometric methods. As the detection limits were down to 0.013 and 0.1 µg ml⁻¹ and quantitation limits were 0.04 and 0.032 µg ml⁻¹ for terbinafine and itraconazole, respectively; the in vitro determination of terbinafine and itraconazole in spiked plasma samples was applicable. The percentage recoveries in biological samples were 97.17 ± 4.54 and 98.75 ± 2.25 for terbinafine and itraconazole, respectively. Water was used as the optimum diluting solvent in the proposed methodology which adds an eco-friendly merit.

在本研究中，对特比萘芬和伊曲康唑进行了低至生物浓度水平的测定。该测定基于通过结合导数和同步分光荧光测定方法来提高分光荧光测定技术的选择性，这使得在 60 nm 的 Δ λ 处彼此存在的情况下，能够在 257 nm 处成功估计特比萘芬和在 319 nm 处伊曲康唑。^{遵循国际协调会议验证指南来充分验证该方法，两种药物在特比萘芬 0.1–0.7 µg ml -1}和伊曲康唑 0.5–4.0 µg ml ^-1范围内获得线性。该方法已成功应用于商业片剂，与对比荧光光度法具有良好的一致性。特比萘芬和伊曲康唑的检测限分别降至 0.013 和 0.1 µg ml ^-1，定量限分别为 0.04 和 0.032 µg ml ^-1；适用于体外测定加标血浆样品中的特比萘芬和伊曲康唑。生物样品中特比萘芬和伊曲康唑的回收率分别为 97.17 ± 4.54 和 98.75 ± 2.25。在所提出的方法中，水被用作最佳稀释溶剂，这增加了生态友好的优点。